Targeting the Binding Function 3 (BF3) Site of the Human Androgen Receptor through Virtual Screening.-Reference-Cited by-同舟云学术

Targeting the Binding Function 3 (BF3) Site of the Human Androgen Receptor through Virtual Screening.

Published:2011-11-18 Issue:24 Volume:54 Page:8563-8573
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Lack Nathan A.¹,Axerio-Cilies Peter¹,Tavassoli Peyman¹,Han Frank Q.²,Chan Ka Hong¹,Feau Clementine³,LeBlanc Eric¹,Guns Emma Tomlinson¹,Guy R. Kiplin³,Rennie Paul S.¹,Cherkasov Artem¹

Affiliation:

1. Vancouver Prostate Centre, University of British Columbia, 2660 Oak Street, Vancouver, British Columbia V6H 3Z6, Canada

2. Structure Based Design Inc., 6048 Cornerstone Court West, San Diego, California 92121, United States

3. Department of Chemical Biology and Therapeutics, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee 38103, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm201098n

Reference39 articles.

1. Cancer facts and figures 2008;American Cancer Society:Atlanta, 2008.

2. 20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer

3. Intermittent Androgen Suppression for Prostate Cancer: Rationale and Clinical Experience

4. Emerging therapies in castrate-resistant prostate cancer

Cited by 136 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in the understanding of androgen receptor structure and function and in the development of next-generation AR-targeted therapeutics;Steroids;2024-10

2. Discovery of Novel Anti‐Resistance AR Antagonists Guided by Funnel Metadynamics Simulation;Advanced Science;2024-03-13

3. Recent advances in dietary androgen receptor inhibitors;Medicinal Research Reviews;2024-01-27

4. Overcoming resistance in prostate cancer with targeted and small molecule-based therapies;Therapy Resistance in Prostate Cancer;2024

5. Characterization of allosteric modulators that disrupt androgen receptor co-activator protein-protein interactions to alter transactivation–Drug leads for metastatic castration resistant prostate cancer;SLAS Discovery;2023-10